Results 111 to 120 of about 3,227,713 (265)

Trajectories of Adherence to Biologics in Patients With Inflammatory Bowel Diseases: A Large‐Scale Multi‐Regional Italian Study Through the VALORE Distributed Database

open access: yesPharmacoepidemiology and Drug Safety, Volume 34, Issue 10, October 2025.
ABSTRACT This study aimed to identify and describe trajectories of adherence to biologics in patients with IBDs and to identify adherence determinants in the Italian real‐world setting. We conducted a retrospective cohort study across 12 Italian regions, including new users of biologics with inflammatory bowel diseases (IBDs), between 2010 and 2019 and
Sabrina Giometto   +34 more
wiley   +1 more source

Secular Trends in the Use of Valproate‐Containing Medicines in Women of Childbearing Age in Europe: A Multinational DARWIN EU Network Study

open access: yesPharmacoepidemiology and Drug Safety, Volume 34, Issue 10, October 2025.
ABSTRACT Background Valproate‐containing medicines (VPA) are first‐line treatments for epilepsy; however, they pose teratogenic risks, restricting their use in women of childbearing age. We aimed to estimate the secular trends in the use of VPA and alternative treatments in young women, and to characterise dose/strength, treatment duration, and ...
Lucía Bellas   +14 more
wiley   +1 more source

Adherence to United European Gastroenterology Guidelines on Diagnosis and Therapy of Immunoglobulin‐G4‐Related Digestive Disease

open access: yesUnited European Gastroenterology Journal, Volume 13, Issue 8, Page 1583-1592, October 2025.
ABSTRACT Introduction United European Gastroenterology (UEG) Guidelines on immunoglobulin G4 (IgG4)‐related digestive disease provides evidence‐based recommendations for the diagnosis and management of IgG4‐related digestive disease. The aim of this study is to evaluate the adherence to recommendations of this IgG4 guideline across centers in Europe ...
Miroslav Vujasinovic   +22 more
wiley   +1 more source

Consenso 2012 da Sociedade Brasileira de Reumatologia para o tratamento da artrite reumatoide

open access: yesRevista Brasileira de Reumatologia
OBJETIVO: Elaborar recomendações para o tratamento da artrite reumatoide no Brasil. MÉTODO: Revisão da literatura com seleção de artigos baseados em evidência e opinião de especialistas da Comissão de Artrite Reumatoide da Sociedade Brasileira de ...
Licia Maria Henrique da Mota   +11 more
doaj  

Expert Perspective: Hematologic Malignancies and Vasculitis

open access: yes
Arthritis &Rheumatology, Volume 77, Issue 10, Page 1305-1316, October 2025.
Michelle L. Robinette, Hetty E. Carraway
wiley   +1 more source

Comparative Effectiveness and Safety of Adalimumab, Secukinumab, and Upadacitinib in Psoriatic Arthritis: A Prospective Cohort Study Based on PARWCH Cohort

open access: yesThe Journal of Dermatology, Volume 52, Issue 10, Page 1527-1535, October 2025.
ABSTRACT Psoriatic arthritis (PsA) is a chronic inflammatory disease, with prevalence among psoriasis patients ranging from 6% to 42% across populations. Although targeted therapies such as adalimumab (ADA), secukinumab (SEC), and upadacitinib (UPA) have demonstrated efficacy in randomized controlled trials, real‐world head‐to‐head comparisons remain ...
Yiyi Wang   +11 more
wiley   +1 more source

IgG4‐Related Disease: Emerging Roles of Novel Genetic Variants, Immune Cell Subsets and Therapeutic Targets

open access: yesAllergy, Volume 80, Issue 10, Page 2738-2754, October 2025.
ABSTRACT IgG4, the least abundant IgG subclass in humans, is increasingly recognised for its involvement in allergic and autoimmune pathologies. Its unique properties, such as the tendency to form half‐molecules (one heavy chain and one light chain) and its generally non‐inflammatory nature, distinguish it from other IgG subclasses.
Louisa Tedesco   +8 more
wiley   +1 more source

Development of an Artificial Intelligence Powered Medication Risk Score Calculator Application

open access: yesBasic &Clinical Pharmacology &Toxicology, Volume 137, Issue 4, October 2025.
ABSTRACT The publication explores the development of the Augmented Medication Risk Score (AUGMERIS) calculator, a web application supported by artificial intelligence, designed to automate the evaluation of medication therapies with the Danish Medication Risk Score (MERIS) method.
Ádám Bertalan   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy